Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$249.59
+1.2%		$244.49
$197.81
▼
$495.55
$33.67B0.311.53 million shs933,713 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$230.70
+3.4%		$252.22
$186.05
▼
$282.15
$14.82B0.35765,396 shs1.14 million shs
Natera, Inc. stock logo
NTRA
Natera
$408.79
+4.6%		$314.82
$157.43
▼
$412.93
$56.33B1.541.28 million shs1.96 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$199.86
+4.8%		$200.44
$42.18
▼
$224.31
$41.34B1.41.96 million shs4.06 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.25%+1.66%+3.96%-14.34%-45.55%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+3.39%-3.49%-8.81%-11.52%+19.36%
Natera, Inc. stock logo
NTRA
Natera
+4.61%+11.60%+21.41%+56.08%+149.40%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+4.78%+1.48%-5.45%+9.76%+359.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$249.59
+1.2%		$244.49
$197.81
▼
$495.55
$33.67B0.311.53 million shs933,713 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$230.70
+3.4%		$252.22
$186.05
▼
$282.15
$14.82B0.35765,396 shs1.14 million shs
Natera, Inc. stock logo
NTRA
Natera
$408.79
+4.6%		$314.82
$157.43
▼
$412.93
$56.33B1.541.28 million shs1.96 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$199.86
+4.8%		$200.44
$42.18
▼
$224.31
$41.34B1.41.96 million shs4.06 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.25%+1.66%+3.96%-14.34%-45.55%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+3.39%-3.49%-8.81%-11.52%+19.36%
Natera, Inc. stock logo
NTRA
Natera
+4.61%+11.60%+21.41%+56.08%+149.40%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+4.78%+1.48%-5.45%+9.76%+359.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.87
Moderate Buy$367.2047.12% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7534.70% Upside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$330.83-19.07% Downside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.96
Moderate Buy$230.1515.16% Upside

Current Analyst Ratings Breakdown

Latest ASND, NTRA, RVMD, and ALNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$267.00
9/21/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$455.00
9/21/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$225.00 ➝ $265.00
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$344.00
9/10/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Overweight$255.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/9/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$215.00 ➝ $230.00
9/9/2026
Natera, Inc. stock logo
NTRA
Natera
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $435.00
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B8.99$2.77 per share90.00$5.97 per share41.81
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.67N/AN/A($2.97) per share-77.68
Natera, Inc. stock logo
NTRA
Natera
$2.71B21.77N/AN/A$12.38 per share33.02
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,699.31N/AN/A$8.44 per share23.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3846.3925.73N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.9026.01N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A40,879.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest ASND, NTRA, RVMD, and ALNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Natera, Inc. stock logo
NTRA
Natera
99.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Stock: Insider Elizabeth Anderson Sells 10,143 Shares
September 24 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-revolution-medicines-nasdaq-rvmd-stock-insider-elizabeth-anderson-sells-10143-shares-2026-09-24/
Andra AP fonden Has $5.28 Million Stock Holdings in Revolution Medicines, Inc. $RVMD
September 24 at 3:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-andra-ap-fonden-has-528-million-stock-holdings-in-revolution-medicines-inc-rvmd-2026-09-24/
Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?
September 23 at 3:24 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-cheap-fda-061325173.html
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Bank of America Analyst Says
September 23 at 1:30 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31040401
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE
September 22 at 10:24 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-wins-fda-221145809.html
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?
September 22 at 10:24 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-deepens-ras-001949336.html
44,928 Shares in Revolution Medicines, Inc. $RVMD Acquired by Nykredit A S
September 22 at 3:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-44928-shares-in-revolution-medicines-inc-rvmd-acquired-by-nykredit-a-s-2026-09-22/
Bank of America Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-bank-of-america-forecasts-strong-price-appreciation-for-revolution-medicines-nasdaq-rvmd-stock-2026-09-21/
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $67,940.84 in Stock
September 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036626
Revolution Medicines (NASDAQ:RVMD) Insider Sells $2,786,969.12 in Stock
September 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036319
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $1,109,567.56 in Stock
September 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036313
Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells $989,625.08 in Stock
September 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036318
Revolution Medicines (NASDAQ:RVMD) CFO Sells $807,519.72 in Stock
September 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036311
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to FTSE All-World Index
September 21, 2026  |  marketscreener.comM
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to FTSE All-World Index
September 21, 2026  |  marketscreener.comM
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 341 Shares of Stock
September 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rvmd-insider-buying-and-selling-2026-09-19/
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Moderate Buy" from Analysts
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032107
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Moderate Buy" from Analysts
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-revolution-medicines-inc-nasdaq-rvmd-receives-average-recommendation-of-moderate-buy-from-analysts-2026-09-19/
Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-alan-sandler-sells-341-shares-of-revolution-medicines-nasdaq-rvmd-stock-2026-09-18/
Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 4,053 Shares
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-revolution-medicines-nasdaq-rvmd-cfo-sells-4053-shares-2026-09-18/
Revolution Medicines (NASDAQ:RVMD) COO Sells 4,967 Shares of Stock
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-revolution-medicines-nasdaq-rvmd-coo-sells-4967-shares-of-stock-2026-09-18/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
Close-up of a carbon fiber surface bearing the AV logo and a camera sensor.
AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone Opportunity
By Ryan Hasson | September 3, 2026
Large haul trucks travel a winding road through an open-pit mine at sunrise or sunset.
Bond Yields Are Pressuring Gold, But Miners May Tell a Different Story
By Jeffrey Neal Johnson | September 8, 2026
A drone with a camera gimbal flies in a dark room above the Draganfly company logo.
Radar Anomaly: Draganfly’s Options Surge Signals Strategy Shift
By Jeffrey Neal Johnson | September 1, 2026
Three-panel composite showing a control room with monitoring screens, solar panels with power lines at sunset, and an illuminated oil refinery.
Defense, Solar, and Refining Stocks Split as the Iran Conflict Raises Energy Risk
By Nathan Reiff | September 9, 2026
Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$249.59 +3.08 (+1.25%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$249.62 +0.03 (+0.01%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$230.70 +7.57 (+3.39%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$242.99 +12.29 (+5.33%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Natera stock logo

Natera NASDAQ:NTRA

$408.79 +18.00 (+4.61%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$411.18 +2.39 (+0.59%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$199.86 +9.12 (+4.78%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$200.95 +1.09 (+0.55%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas